People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Pharmaceuticals, Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Anaptysbio Inc | — | Pharmaceuticals | Series C | $50.8M | $1.4B | 2011 |
| Sirion Holdings, Inc. | — | Pharmaceuticals | Series B | $30.2M | $941.4M | 2009 |
| ReVision Therapeutics, Inc. | — | Biotechnology | Seed | $3.4M | $22.2M | 2010 |
| Eikonizo Therapeutics, Inc. | — | Pharma | Seed | $2.4M | $14.1M | 2018 |
Kevin Kinsella at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kevin Kinsella on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Barrett | 1 | 18 |
| James Topper | 1 | 12 |
| Heath Lukatch | 1 | 10 |
| Tiba Aynechi | 1 | 9 |
| David Weber | 1 | 8 |
| Carol Gallagher | 1 | 6 |
| Charles Cohen | 1 | 6 |
| Douglas Downs | 1 | 6 |
| BARRY BUTLER | 1 | 6 |
| James N. Topper | 1 | 5 |
| Robert Hoffman | 1 | 5 |
| Andrew Schiff | 1 | 5 |
| Anthony Maida | 1 | 5 |
| Jay Lichter, Ph.D. | 1 | 5 |
| Stacie Weninger | 1 | 4 |
| John Schmid | 1 | 4 |
| Todd Creech | 1 | 4 |
| William Shaw | 1 | 4 |
| J Leighton Read | 1 | 2 |
| Carol N. Gallagher | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.